• 1
    Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 2005; 96: 9649.
  • 2
    Pandha H, Birchall L, Meyer B et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J. Urol. 2006; 176: 225561.
  • 3
    Clezardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr. Med. Chem. 2003; 10: 17380.
  • 4
    Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 2003; 9: 28937.
  • 5
    Schilbach K, Geiselhart A, Handgretinger R. Induction of proliferation and augmented cytotoxicity of γδ T lymphocytes by bisphosphonate clodronate. Blood 2001; 97: 291718.
  • 6
    Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001; 296: 23542.
  • 7
    Kikuno N, Urakami S, Nakamura S, Shiina H, Igawa M. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone. Int. J. Urol. 2007; 14: 824.
  • 8
    Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J. Immnol. 2001; 167: 50928.
  • 9
    Campbell SC, Novick AC, Bukowski RM. Renal tumors. In: KavoussiLR, NovickAC, PartinAW, PetersCA, WeinAJ (eds). Campbell-Walsh Urology. Saunders, New York, 2007; 1567637.
  • 10
    Yuasa T, Nogawa M, Kimura S et al. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon-α/β-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin. Cancer Res. 2005; 11: 8539.